PDL1 ADC for PDL1 Positive Tumors

Partnering Immuno-Oncology

Life Saving Cancer Treatments!

Extensive Inventory of Proprietary Co-stimulatory Agents and Checkpoint Inhibitors

= Multiple Revenue Opportunities

PD-L1 Inhibitors

Revolutionized Immuno-Oncology

  • PD-1 is a checkpoint protein on immune cells called T cells
  • Normally acts as a type of “off switch” that helps keep the T cells from attacking other cells in the body
  • Does this when it attaches to PD-L1, a protein on some normal (and cancer) cells
  • When PD-1 binds to PD-L1, it basically tells the T cell to leave the other cell alone
  • Some cancer cells have large amounts of PD-L1, which helps them hide from an immune attack.

Molecular Templates (“MTEM”)

Engineered Toxin Bodies (ETBs) with Lanier’s Proprietary PD-L1 Inhibitor

  • ETBs platform represents a new class of targeted therapy with unique biological properties
  • ETBs work through a unique intracellular mechanism of action: enzymatic and permanent ribosome inactivation
  • A Phase 1 study in relapsed/refractory patients with PD-L1 expressing tumors paid out initial milestone

PD-L1 Checkpoint Inhibitor is Involved in Many Tumor Types